copolymer 1 (glatiramer acetate)

Subscribe to Selected New Research on copolymer 1

413 relevant articles (57 outcomes, 81 trials/studies) found for this Drug

Description: Israeli drug (Teva Pharmaceutical); a synthetic polypeptide consisting of L-Ala, L-Glu, L-Lys, and L-Tyr; produces antigen-suppressor cells specific for myelin-based protein; potential drug for treating multiple sclerosis

Also Known As:

glatiramer acetate; Copaxone; Aventis brand of copolymer 1; Teva brand of copolymer 1; copolymer-1

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins

Peptides: 16375

copolymer 1: 413

Experts

1.	Wolinsky, J S: 11 articles (01/2008 - 01/2000)
2.	Aharoni, Rina: 9 articles (08/2008 - 09/2003)
3.	Arnon, Ruth: 9 articles (08/2008 - 09/2003)
4.	Johnson, K P: 9 articles (07/2007 - 08/2000)
5.	Lisak, R P: 9 articles (06/2006 - 08/2000)
6.	Filippi, Massimo: 6 articles (03/2008 - 08/2003)
7.	Ziemssen, Tjalf: 6 articles (01/2008 - 11/2002)
8.	Hohlfeld, Reinhard: 6 articles (10/2007 - 11/2002)
9.	Ford, C C: 6 articles (06/2006 - 08/2000)
10.	Wolinsky, Jerry S: 5 articles (01/2007 - 08/2003)

Related Diseases

1.	Multiple Sclerosis 08/01/2000 - "This study demonstrates the sustained efficacy of glatiramer acetate in reducing the relapse rate and in slowing the accumulation of disability in patients with relapsing forms of multiple sclerosis. " 02/01/2009 - "The cumulative evidence for the long-term clinical efficacy of glatiramer acetate is consistent with its dual mechanism of action, reassures the physician that glatiramer acetate can really help improve patient care over the long term, and may contribute to a more positive view of prognosis for patients with multiple sclerosis." 08/01/2003 - "Three randomized, double-blind, placebo-controlled trials have shown that glatiramer acetate (GA) is effective in reducing relapse rate in patients with relapsing-remitting (RR) multiple sclerosis (MS). " 10/31/2009 - "We assessed the efficacy of early treatment with glatiramer acetate in delaying onset of clinically definite multiple sclerosis. " 12/01/2006 - "BACKGROUND: Glatiramer acetate has been shown to be effective in reducing the relapse and improving the disability of patients with multiple sclerosis. " Order ALL the reference details at left...
2.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/01/1997 - "Copolymer 1 (Cop-1) is a synthetic amino acid copolymer effective in suppression of experimental allergic encephalomyelitis (EAE). " 04/01/1996 - "Copolymer 1 is a synthetic amino acid copolymer, effective in suppression of experimental allergic encephalomyelitis (EAE) induced in a variety of species. " 12/01/2004 - "Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies." 04/01/1996 - "Laboratory studies have shown that copolymer 1 prevents or modifies experimental allergic encephalomyelitis in several mammalian species. " 10/01/2007 - "CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis." Order ALL the reference details at left...
3.	Relapsing-Remitting Multiple Sclerosis 05/01/2007 - "Glatiramer acetate (GA) is effective in reducing clinical and magnetic resonance imaging (MRI) activity in relapsing-remitting multiple sclerosis (RRMS). " 01/01/2009 - "The current study was conducted to evaluate the efficacy of glatiramer acetate (GA), an immunomodulatory drug approved for the treatment of relapsing remitting multiple sclerosis, in preventing the death of C57Bl/6J mice infected with Plasmodium berghei ANKA. " 03/20/2007 - "OBJECTIVE: To evaluate the safety, tolerability, and efficacy of glatiramer acetate (GA) 40 mg daily vs the approved 20-mg formulation in relapsing-remitting multiple sclerosis. " 05/01/2008 - "To evaluate the safety and efficacy of long-term glatiramer acetate (GA) therapy, 46 patients with relapsing-remitting multiple sclerosis (RRMS) were treated for up to 22 years in an ongoing, open-label study. " 02/01/2009 - "Similar findings have been made in observational studies in the long-term follow-up of patients with relapsing remitting multiple sclerosis treated with glatiramer acetate under a compassionate use programme in France and in a patient registry in Argentina. " Order ALL the reference details at left...
4.	Disease Progression 09/01/2009 - "CONCLUSION: This evaluation suggests that IFN Beta-1a SC injection, IFN Beta-1b SC injection, and glatiramer acetate represent the most cost-effective DMDs for the treatment of RRMS, where cost-effectiveness is defined as cost per relapse avoided, assuming that (a) the RRR in relapses and disease progression steps calculated from multiple DMD placebo-controlled clinical trials reflect real differences among DMDs over 2 years; and (b) resource unit costs derived from published sources reflect economic consequences of relapses and disease progression." 11/01/2005 - "The disease-modifying treatments, IFN-beta and glatiramer acetate, have been widely available over the last decade and have shown a beneficial effect on relapse rate and magnetic resonance imaging parameters of disease activity; however, their effect on disease progression and disability is modest. " 01/01/2004 - "Glatiramer acetate did not show any significant effect on disease progression, measured as a sustained worsening in the Expanded Disability Status Scale (EDSS). " 06/01/2005 - "Despite limitations of the study design, this report confirms the sustained efficacy of glatiramer acetate in reducing the disease progression in patients with relapsing-remitting multiple sclerosis treated in day-to-day clinical practice." 06/01/2004 - "The immunomodulatory drugs interferon beta and glatiramer acetate are only partly effective in reducing the relapse rate, slowing disease progression, and diminishing the number and volume of lesions on MRI. " Order ALL the reference details at left...
5.	Fatigue 01/01/2008 - "CONCLUSION: Treatment with glatiramer acetate was associated with a significant improvement in fatigue symptoms and a marked reduction in absence from work. " 07/01/2004 - "Logistic regression analysis confirmed the association between glatiramer acetate use and improved fatigue, after accounting for baseline group differences. " 01/01/2008 - "The objective of this prospective naturalistic study was to evaluate the impact of glatiramer acetate on fatigue and work absenteeism. " 11/01/2002 - "Some recent studies suggest the positive effects of drugs on fatigue may be via reducing the inflammatory activity, such as for glatiramer acetate." 02/01/2009 - "There is growing evidence that immunomodulatory treatments, in particular glatiramer acetate, improve fatigue symptoms in patients with multiple sclerosis." Order ALL the reference details at left...

Related Drugs and Biologics

1.	copolymer 1 (glatiramer acetate)
2.	Interferon-beta
3.	Amino Acids
4.	Interferons
5.	Mitoxantrone (Novantrone)
6.	HLA-DR2 Antigen (HLA DR2 Antigen)
7.	interferon beta-1b (Betaseron)
8.	interferon beta 1a
9.	natalizumab (Tysabri)
10.	Gadolinium

Related Therapies and Procedures

1.	Therapeutics
2.	Lasers (Laser)
3.	Injections
4.	Immunotherapy
5.	Investigational Therapies (Experimental Therapy)

Best Treatments:
Research Summary Report
on Multiple Sclerosis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 519 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>